000			01808 a2200469 4500
005			20250516002717.0
264		0	_c20111122
008			201111s 0 0 eng d
022			_a1873-7064
024	7		_a10.1016/j.neuropharm.2010.09.002 _2doi
040			_aNLM _beng _cNLM
100	1		_aScullion, G A
245	0	0	_aChronic treatment with the α2-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APP×PS1 transgenic mice without altering β-amyloid plaque load or astrocytosis. _h[electronic resource]
260			_bNeuropharmacology _c
300			_a223-34 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdrenergic alpha-2 Receptor Antagonists _xadministration & dosage
650	0	4	_aAging _xgenetics
650	0	4	_aAmyloid beta-Peptides _xbiosynthesis
650	0	4	_aAmyloid beta-Protein Precursor _xbiosynthesis
650	0	4	_aAnimals
650	0	4	_aAstrocytes _xdrug effects
650	0	4	_aGliosis _xdrug therapy
650	0	4	_aHumans
650	0	4	_aLongitudinal Studies
650	0	4	_aMemory Disorders _xgenetics
650	0	4	_aMice
650	0	4	_aMice, Inbred C57BL
650	0	4	_aMice, Transgenic
650	0	4	_aPiperoxan _xadministration & dosage
650	0	4	_aPlaque, Amyloid _xdrug therapy
650	0	4	_aPresenilin-1 _xbiosynthesis
650	0	4	_aPyrroles _xadministration & dosage
650	0	4	_aReceptors, Adrenergic, alpha-2 _xphysiology
650	0	4	_aTreatment Outcome
700	1		_aKendall, D A
700	1		_aMarsden, C A
700	1		_aSunter, D
700	1		_aPardon, M-C
773	0		_tNeuropharmacology _gvol. 60 _gno. 2-3 _gp. 223-34
856	4	0	_uhttps://doi.org/10.1016/j.neuropharm.2010.09.002 _zAvailable from publisher's website
999			_c20180847 _d20180847